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Abstract 
Randomized, controlled clinical trials, although important for ensuring safety and efficacy, 
are criticized for being an inadequate validation process for certain medical innovation 
modalities and conditions. The main limitations and causes for critique are high costs, long 
duration, low patient recruitment, design rigidity and ethical issues. 
At the same time, there is growing evidence that patients and their family members 
innovate in treatments, therapies, and medical devices. These patient innovators are 
increasingly recognized as an important source of innovation. Although there is a fairly 
complex structure developed to formally validate healthcare products, little is known about 
the paths patient innovators take to validate their solutions before involving health regulators. 
In this context, we attempt to answer the following research questions: What are the 
patterns of the validation processes undertaken by patient innovators for their innovations? 
How can current practices of patient innovation validation be improved from its comparison 
with observational studies and clinical trials? 
To address these questions, we study cases of patient innovators who attempted to share 
their innovations with other patients. More specifically, we structure the observed processes 
of patient innovation diffusion as a process model for an iterative observational trial process 
in which incremental validation of the innovation is performed by diffusing it to other patients. 
We contrast this process with a general streamlined process of randomized clinical trials. 
We argue learning from the patient innovators practices is important for discussing viable 
frameworks and structures for improving the safety and efficacy of these processes. We 
discuss related implications to innovation research, management and policy.  
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Louis Plante is a patient with cystic fibrosis, a disease that causes “the body to produce 
unusually thick, sticky mucus” that “clogs the lungs and leads to life-threatening lung 
infections” (CF Foundation, 2013). One day, he was forced to leave a concert due to extreme 
coughing. After realising that this episode was likely caused by the fact that he was standing 
next to one of the concert speakers, he thought that maybe he could develop a device that, 
with the use of ultrasounds, would allow him to increase his release of mucus by coughing, 
thus decreasing the risks of lung infection. Louis proceeded to invent the “Frequencer”, an 
“electro-acoustical transducer” that dramatically increased his quality of life, not only because 
it was much more comfortable than the standard treatment at the time, which involved 
periodical physical percussion of the thorax in an inclined position to increase expectoration, 
but also because the amount of mucus he was releasing was significantly larger. After 
realising that the Frequencer was working for him informally, and getting better with each 
modification, Louis proceeded to discuss with his doctor ways to prove the effectiveness of 
his invention. Together, they designed a small trial and performed it on him. Afterwards, they 
tried the device on two other patients with pulmonary conditions, and it didn’t work for them. 
The device was further altered as a consequence. Then a series of more successful trials 
were developed in a hospital setting, after a white paper on the scientific bases for the 
invention was written. Eventually, Louis founded his own company, but he was still looking 
for further proof of the effectiveness of his device: he made his Frequencer able to receive 
data from an electronic scale with via USB and to send results of the expectorated mucus 
weight back to him electronically. 
A patient from Florida, USA, suffering from skin cancer, experimented with applying a 
mixture of chilli peppers and alcohol on his skin and realised that this had an impact on his 
lesions. He based his experiments on having done literature research on the use the active 
ingredient of hot peppers in the treatment of other ailments. He tried to approach doctors, 
hospitals and universities with the intention of perform trials on other patients, but nobody 
followed through. Nevertheless, he has been responding to requests for help from people 




other people, he experimented with higher concentrations of his medicine. Unfortunately, 
because he was unable to perform any structured trial or study, the effect of his invention is 
not, to this date, conclusive. 
These are two examples of patient innovators who after partially or completely solving 
their health problems were interested in helping others. In order to do so, they looked for 
advice in different places, consulted with many people, changed their inventions due to 
feedback they collected and then had other people test them on themselves. However, they 
attempted different validation paths, rendering their inventions diverse success results.  
The phenomenon of patient innovation has been recently documented: patients and 
caregivers have been shown to innovate in treatments, therapies and medical devices 
(Habicht, Oliveira, & Shcherbatiuk, 2012; Shcherbatiuk & Oliveira, 2012). Patients as a 
source of medical innovation may be of especial importance in this time of rising health care 
costs and stalled innovation in medicine. 
Health expenditure is a very important part of the economies of developed countries. In 
2012, it represented 9,3% of total GDP in OECD1 countries. Without taking into account the 
recent stagnation due to the economic crisis, health expenditure has grown steadily from 
2001 to 2009, between 4 and 5%2 each year. This increase, of which some is on research 
and development, has however been accompanied by a stagnation of breakthroughs in 
medical innovation, measured by the number of new drugs discovered per year (Landers, 
2004).  
The inefficiencies of the current health system, with mostly profit-driven research and 
development of novel pharmaceuticals and other therapies are also evident in rare diseases. 
With an estimated number of diseases between 6,000 and 8,0003, some with only a handful 
of patients, the current pace of medical innovation will never be able to successfully solve or 
manage all these conditions. The lack of alternatives available in the market creates higher 
needs to patients, which serve as incentives to innovation, as shown by Habicht et. al (2012). 







In this work, we study cases of patient innovators who attempted to share their 
innovations with other patients, identifying the main steps in the process, difficulties they 
face, and the innovators’ responses. In order to do this, we try to address the following 
research question in this work: 
• What are the patterns of the validation processes undertaken by patient innovators 
for their innovations? 
• How can current practices of patient innovation validation be improved from its 
comparison with observational studies and clinical trials? 
Learning from the patient innovators practices is important for discussing viable 
frameworks and structures for improving the safety and efficacy of these processes. We 
discuss related implications to both innovation research and policy.  
In section 2 of this work, we review the existing literature on patient innovation, integrating 
it in the relevant context of user innovation. We also provide an overview on the current 
standards of practice in validation of medical innovations in the United States and Europe, 
providing basis for contrast with observed practices of patient innovators. Section 3 
describes the methodology of the research. Section 4 includes the results of the surveyed 
sample and a proposal of a theoretical model. We structure the observed processes of 
patient innovation diffusion as a process model for an iterative observational trial process in 
which incremental validation of the innovation is performed by diffusing it to other patients. 
This process model is characterized by feedback loops on every step, enabling the continued 
improvement of both the innovation and the study design. Section 5 provides interpretation 
and contextualisation of such results within the literature and interviews, comparison of the 
proposed model against the existing formal model of validation, and implications of the study 
for research and policy decision making.  
2. Literature Review 
2.1. Patient Innovation 
Patients have not typically been considered relevant sources of innovation in the health 




knowledge. However, recent research has shown that users create radical innovations (e.g. 
Røtnes and Staalesen 2009), and patients and caregivers have been shown to create 
innovations in the medical field, in the form of treatments, therapies and medical devices 
(Habicht et al., 2012; Shcherbatiuk & Oliveira, 2012). 
Patients, caregivers and family members who innovate are considered patient innovators 
(PI) when they are the first ones to create a medical innovation with the primary purpose of 
using it, as opposed to being producer innovators, who develop innovations with the main 
objective of obtaining profit from them (Shcherbatiuk & Oliveira, 2012; von Hippel, 2005).  
The study of patient innovation is part of the larger academic field of user innovation, 
which studies the importance of user in the creation of novel products and services. 
2.1.1. User Innovation 
Only in recent decades did the academic community start acknowledging the importance 
of the phenomenon of user innovation. Producer innovation occurs when it is developed by 
individuals or firms who expect to benefit from selling a product or service, whereas user 
innovation happens when it is developed by individuals or firms who expect to benefit from 
the use of a product or service (von Hippel, 2005). Raasch and von Hippel (2012) show that 
the two paradigms, user innovation paradigm and producer innovation paradigms, have 
important interactions, namely the “competition and complementarity between the 
innovations diffused via the two channels”. 
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Big manufacturers and producers tend to develop strategies of market segmentation, and 
to produce products or services that match what they perceive are the needs of these 
segments. However, when the heterogeneity of the user’s needs is high, the segmentation 
tends to be insufficient, and this strategy of “one size fits all” renders many users dissatisfied 
with the solutions that are available in the market. In an analysis of Apache security software, 
it was found that a high heterogeneity of the needs in the market accompanied a high 
willingness to pay to get software improvements, and that innovating users were more 
satisfied than others (Franke & von Hippel, 2003). Similarly, most medical technologies and 
pharmaceuticals are developed with the purpose of reaching the many rather than the few, 
sometimes leaving the immediate needs of some patients unattended. 
Some patients and caregivers, having an acute, often very specific and hardly-
transferable perception of their needs, are well positioned to develop themselves solutions to 
their problems. The unique knowledge of user needs, both idiosyncratic and of a larger user 
group, is acquired by users through their own use (von Hippel, 1986) which, in the case of 
patients, is translated as their everyday lives with their conditions. Information “stickiness”, 
meaning the difficulty, cost or impossibility of transferring information, decreases the capacity 
of users (patients) to advise producers of their needs, often shifting the locus of innovation to 
the user (von Hippel, 1994).  
Research shows that user innovation is more prevalent among “lead users”, a subset of 
the population of users who face needs before the market (are trend leaders) and who 
benefit significantly from the development of a solution for those needs (von Hippel, 1986). 
The importance of lead user has been shown empirically by a number of studies of the “lead 
user method”, using methods of identifying the two characteristics stated above and their 
correlation with a higher propensity for user innovation (Franke, Von Hippel, & Schreier, 
2006; Herstatt & von Hippel, 1992; Urban & von Hippel, 1988). 
2.1.1.1. Importance of User Innovation 
Although the economic importance of user innovation in medicine has not yet been 
soundly established, it has been proven to be an important phenomenon in a variety of fields, 
including industrial products such as scientific instruments (Riggs & von Hippel, 1992), 




systems (Morrison, Roberts, & von Hippel, 2000), construction materials (Herstatt & von 
Hippel, 1992), security software (Franke & von Hippel, 2003); consumer products such as 
sports equipment (Baldwin, Hienerth, & von Hippel, 2006; Franke & Shah, 2003; Franke et 
al., 2006; Lüthje, Herstatt, & von Hippel, 2005; Shah, 2000) , automobiles (Kline & Pinch, 
1996) and juvenile products (Shah & Tripsas, 2007); and services such as banking (Oliveira 
& von Hippel, 2011). Habicht et al. (2012) found that in the field of medical devices for cystic 
fibrosis, 50% were developed by patients. 
Recent studies have shown that there is a significant percentage of people over 18 years 
old who engage in user-innovations. In the US it was determined to be 6,1%, in the UK 5,2% 
and 3,7% in Japan (von Hippel, Ogawa, & de Jong, 2011), supporting the argument that the 
phenomenon is relevant and still under-studied. 
2.1.1.2. Diffusion of User Innovations 
When patient innovators share their solutions with others, they may end up saving other 
patients’ lives (Habicht et al., 2012). In order to being able to save many lives, patients and 
other user innovators who successfully created a novel solution are faced with a challenge: 
they can become user entrepreneurs, they may sell or license their idea, they can freely 
reveal their idea in a community, or do nothing to diffuse their innovation and perhaps a 
valuable contribution to the world gets lost. 
Diffusion of innovations by users may thus generally be separated between market 
diffusion, in which they either become user entrepreneurs or sell or license their innovation 
for commercialisation by an existing company, and peer-to-peer diffusion, to individuals or an 
established community. The first is defined as the transfer of an innovation involving a 
transaction or some form of exchange, whereas the later involves negligible cost in the 
transfer of innovation-related information to potential adopters (Raasch & von Hippel, 2012). 
We also consider diffusion to non-potential adopters as a valid form of peer-to-peer diffusion, 
given that diffusing the knowledge of existence of a certain innovation through non-adopters 
may be a means for reaching other potential adopters. Patient innovators can therefore not 
only diffuse to other patients or doctors, who may be potential adopters, but also to their 
friends and family, their lawyers and their online hobby communities, who may act as further 




performed in sequence, whereby a user could share their innovation to their community and 
later become a user entrepreneur. 
The user innovation paradigm suggests that the main drivers for user innovation are the 
expected benefit from developing (Raasch & Hippel, 2012) and from using the solution 
created (von Hippel, 2005). Unlike producers, who profit from diffusion, users may benefit 
very little from the use of others. Therefore, diffusion is considered an externality to the 
process of user innovation. This means that all effort in diffusing will only be exercised while 
its benefits are expected to be superior to the costs of diffusing the innovation (Raasch & von 
Hippel, 2012). One way users have been found to increase the associated benefits is by 
creation of a community brand as by-product of its member interactions, as in an empirical 
case of the Apache software community (Füller, Schroll, & von Hippel, 2013). 
We explore further the phenomenon of user entrepreneurship, which was the path 
undertaken by most of the sample of patient innovators present in this work. 
Entrepreneurship is the existence, discovery, evaluation and exploitation of opportunities to 
create future goods or services (Shane & Venkataraman, 2000). It is often defined by the 
creation of new organisations, although this is not a necessary condition for entrepreneurial 
activity to occur: the service or good created may be sold to others or rise in the midst of an 
existing organisation (Shane & Venkataraman, 2000). 
The main conceptual difference between entrepreneurs in general and user-
entrepreneurs is that the latter not only commercialize the new product or service but are 
also users of it. There are two types of user-entrepreneurs: professional-user entrepreneurs, 
who use their innovations in a professional setting; and end-user entrepreneurs, who employ 
their innovations in their day-to-day lives (Shah & Tripsas, 2007).  
User-entrepreneurs may start selling their product or service and thus become 
manufacturers or providers either by formal evaluation of market potential or through 
previous indications for demand by public exposure of the innovation. The latter case is 
named the “accidental entrepreneur”, whereby development, experimentation, adaptation 
and some adoption are performed before formal evaluation (Shah & Tripsas, 2007) 
Users can choose to either sell their ideas to other users or companies and now, with 




service, shipment) becoming “causal entrepreneurs” or even create entirely new companies 
(von Hippel et al., 2011). 
The phenomenon of user entrepreneurship has been found to be relevant in a variety of 
industries, including radical sports equipment – windsurfing, skateboarding and 
snowboarding (Shah, 2000), mountain bicycle (Luthje, Herstatt, & von Hippel, 2002) and 
kayak rodeo (Baldwin et al., 2006) – the stereo components industry (Langlois & Robertson, 
1992) and juvenile products (Shah & Tripsas, 2007). In the field of medical services and 
devices industry, evidence has also been collected of relevant existence of user-
entrepreneurs (Lettl, Herstatt, & Gemuenden, 2006; Shcherbatiuk & Oliveira, 2012). 
Also relevant in the study of user entrepreneurship is the model of how user innovations 
become commercial products developed by Baldwin et al. (2006). In this model users start by 
recognising a “design space” – a set of new innovation possibilities – before creating their 
innovation, then join communities due to the higher efficiency of collective innovation and 
later emerge as user-manufacturers. They theorise that innovators benefit from freely 
revealing their designs with other user-innovators, and that at a certain point user-purchasers 
emerge, who are more interested in buying than in developing the new designs for 
themselves. The phenomenon of free revealing in communities has been shown to take 
place in communities of sports enthusiasts, often in informal settings (Baldwin et al., 2006; 
Franke & Shah, 2003). The main advantages of freely revealing are the ability of other users 
to test, suggest improvements and diffuse innovations, thereby progressively signalling the 
features and designs that may become commercially attractive. Nevertheless, there is also 
evidence that most consumers do not actively share knowledge of their innovation, due to 
lack of incentives (von Hippel et al., 2011). 
Similarly, users who have decided to become entrepreneurs often share with others 
before formally venturing into commercialisation, receiving suggestions for improvements 
and diffusion through word of mouth, thus benefitting from the contributions and feedback of 
communities (Shah & Tripsas, 2007). Users in communities may even serve as beta-testers, 
providing iterative feedback to improve the solution (Franke & Shah, 2003).  
The user entrepreneurship model proposed by Shah and Tripsas (2007) shows how 




on observing them publicly use their innovation and from the members of their community 
due to freely revealing. After this, they may or may not recognise the opportunity for 
commercialising their innovation. 
Feedback loops are also very important in medicine. Drugs follow an innovation process 
where larger changes occur at the pre-clinical stages, whereas medical devices have higher 
incremental change throughout the trial process, ranging from the device to the design of the 
trial or post-operation indications (Christensen et al., 2007). Gelijns and Rosenberg (1994) 
refer to the “pill” and endoscopes as landmarks of how feedback loops from patients and 
clinicians play a major role in incremental innovations, adding new uses for drugs as 
examples of such innovation in a clinical practice setting. These feedback loops show that 
medical innovation is not only caused by technological breakthroughs but also by iterative 
modifications, and this information could help shape the design of clinical trials (Christensen 
et al., 2007). 
Motivations for diffusion, sources, and types of feedback and the impact of feedback in 
the innovations themselves may still be largely understudied in the field of user innovation. 
To the best of our knowledge, it has not yet been explored in the context of patients and 
caregivers who innovate and diffuse their knowledge to others.  
To be able to contrast standard medical innovation with informal innovations that patients 
and caregivers are creating when faced with their diseases, we need a general outlook at 
medical innovation and the forms of scientific validation of innovations that constitute the 
current standard in medicine, their main characteristics and limitations. 
 
2.2. Current Practices of Validation of Medical Innovation in 
Europe and the USA 
Innovation in medicine includes the scientific, technological, and clinical developments 
that originate new medical products, processes, or procedures, which may be diagnostic, 
therapeutic, preventive, or administrative (Rettig, 1994). We may separate some of them into 





The requirements of health regulators and the modalities of the innovations influence the 
research designs used to assess risk and effectiveness of innovations (Christensen et al., 
2007), as well as the legal requirements for approval of innovations. In the USA, surgical 
procedures and clinical practices, the latter defined as the definition of the standard 
procedures, pharmaceuticals, and devices used to treat a particular disease, follow a less 
formal process than medical devices or drugs (Christensen et al., 2007). Legal oversight is 
limited or non-existent, and clinical testing may be required only by insurance companies, 
responsible for paying for such practices (Friedman, Furberg, & DeMets, 2010).  
Due to the intrinsic differences in the level of risk and novelty of pharmaceuticals and 
medical devices, these two types of innovation require different processes of evaluation and 
validation. In the USA, the Food and Drug Administration (FDA) requires that most new 
drugs (under the name of investigational new drugs, or INDs) undertake a multi-phase 
process (FDA, 2013a). On the other hand, medical devices’ regulatory requirements concern 
mostly engineering and technical characteristics, with clinical data being more important the 
riskier the device, both in the USA and in Europe (Friedman et al., 2010; Kramer, Xu, & 
Kesselheim, 2012). 
The number of yearly approvals of drugs and medical devices is very different, which may 
hint at both the differences in difficulty to create novel products and contrasting approval 
speeds between the two innovation modalities: in 2012, FDA’s Centre for Drug Evaluation 
and Research approved 39 new drugs and 63 supplements for already approved drugs, 
including new uses for drugs (CDER, 2012, 2013). In contrast, 3130 new devices were 
approved, with additional 894 modifications to previously approved devices accepted by the 
FDA. 
2.2.1. Types of Medical Studies 
There are two main types of studies to test innovations in medicine: experimental and 
observational. The first type requires the study subjects to undergo some type of therapy, 
whereas observational studies (OS) are those in which the scientist only observes 
interactions that exist between subjects of the study and other variables, not controlled by the 




observations can be recorded after the test was initiated, or can be obtained from past 
records or events), experimental trials are only prospective (Friedman et al., 2010). 
Experimental trials typically take the form of clinical trials, either randomized or non-
randomized. On the other hand, the most common types of observational studies are cohort 
and case-control studies. 
2.2.1.1. Experimental studies 
Clinical trials are typically considered the gold standard of medical trials (Campbell & 
Fitzpatrick, 2000; Concato, Shah, & Horwitz, 2000; Scott & Baker, 2007). Because they are 
experimental and not observational, clinical trials involve intervention of one or multiple 
diagnostic, preventive, or therapeutic drugs, biologics, devices, regimens, or procedures. 
(Friedman et al., 2010). 
The trials most favoured in current medicine are the controlled, double blinded, 
randomized trials. The control may take the form of placebo, active treatment, dose 
comparison or may be historically derived, but the selection of the trial subjects should be 
randomized when the control is concurrent with the active arm of the trial (Mitsumoto, 
Dorsey, Beck, Kieburtz, & Griggs, 2009) 
2.2.1.1.1. General Crit ic ism and Limitat ions 
Randomized, controlled clinical trials, although important for ensuring safety and efficacy, 
are frequently criticized for being an inadequate validation process for certain innovation 
modalities and conditions. The main causes for critique and limitations are their high costs, 
long duration, low patient recruitment, design rigidity, short-term analysis of adverse effects 
and ethical issues. 
The estimated capitalized costs of the development process of a new drug in the USA 
have been estimated to range from $100 million to $1 billion, with a prominent study which 
includes the costs of the failed pharmaceuticals providing an average at approximately $802 
million, of which time costs account for approximately 50% (DiMasi, Hansen, & Grabowski, 
2003; Field & Boat, 2011; PhRMA (Pharmaceutical Research and Manufacturers of 
America), 2007). This generates a high barrier of entry for trials, usually only possible for 




The duration is an issue reflected not only in terms of cost for sponsors but also as 
opportunity cost for patients in desperate need for new, more effective treatments. The 
average time for a Phase III cancer clinical trial has been calculated to take a median of 2,5 
years, ranging from approximately 435 to 1,604 days (Dilts, Cheng, Crites, Sandler, & 
Doroshow, 2010), while the entire clinical process (Phases I, II and III) was estimated to take 
about 7,5 years from the beginning of clinical testing to marketing. The entire “bench to 
bedside” process takes between 10 and 15 years (DiMasi et al., 2003). 
Cancer Therapy Evaluation Program (CTEP) sponsored trials between 2000 and 2007 
showed that about 40% failed to achieve minimum patient recruitment levels (Stewart, 
Whitney, & Kurzrock, 2010). While some will do with a lower number of patients, other 
estimates claim that 13% of trials do not even start due to poor patient accrual (Prescott, 
Counsell, Ross, & Devon, 1999). The main reasons pointed out for difficulties in recruitment 
are related to narrow patient eligibility criteria, unwillingness of patients to participate in trials 
and difficulties in reaching to patients (Lovato, Hill, Hertert, Hunninghake, & Probstfield, 
1997). 
A relevant limitation of clinical trials concerns the lack of flexibility in its design, given that 
it can only verify or deny a hypothesis (Cooper, 2012), whereas data-set based observational 
studies may have more flexibility on the analysis and the research questions. This flexibility 
allows for the analysis of data to generate itself new research questions without the need to 
undergo further interventions with patients. The same applies for analyses of long-term 
effects on patients (Christensen et al., 2007). 
The Declaration of Helsinki of the World Medical Association, although bearing no legal 
force, is internationally recognised as the cornerstone of ethics in human research (Binns & 
Driscoll, 2000). It postulates that experimenting on human subjects should occur after proper 
laboratory and animal testing, that the potential benefits of experimenting have to be higher 
than the predicted risks, that the interests of the individual are more important than the 
interests of society, that any investigation should be approved by an ethics committee (or 
IRB), that individuals have to be fully aware of the risks and consent to participate and that 
impact on the patients’ health should be minimised (Binns & Driscoll, 2000; World Medical 




randomized controlled trials. There are clear ethical issues with randomizing patients when 
there is no current alternative standard of care (offering some a possibility of cure and the 
control group no possibility of cure) and with performing sham (placebo) surgeries to patients 
(Buchwald, 1997). Furthermore, studying risk factors cannot be performed via clinical trial 
because it is unethical to expose subjects to factors that may cause them any harm or 
disease (Stroup et al., 2000). Ethical issues are very often raised as an argument against the 
use of randomized clinical trials and testing through observational studies (Benson & Hartz, 
2000; Naylor & Guyatt, 1996). 
2.2.1.2. Observational Studies 
Observational studies are an epidemiological instrument, defined as the process of 
empirical association between alterations in a certain variable, usually either an exposure or 
an intervention, and changes in another variable of interest (Stroup et al., 2000). They can be 
used to determine causality, riskiness and effectiveness in situations where, due to ethical 
issues or others, randomization is not possible or advisable (Benson & Hartz, 2000; 
Christensen et al., 2007; Naylor & Guyatt, 1996). The most common forms of observational 
studies are case-control studies and cohort studies. Contrarily to controlled, randomized 
clinical trials, observational trials have no randomization of subjects at the initial stage, rather 
using statistical techniques to avert bias (Christensen et al., 2007). 
Case-control studies are retrospective analyses in which the groups of participants are 
defined on the basis of presence of absence of a certain outcome or condition of interest, 
such as a disease. Cohort studies, on the other hand, can be retrospective (historical 
cohorts) or prospective, and the participants are selected on the basis of presence or 
absence of a certain variable, either an exposure or an intervention (e.g. smoking); there is 
no randomization in the allocation of the control (Christensen et al., 2007; Friedman et al., 
2010; Ioannidis & Haidich, 2001). 
2.2.1.2.3. General Crit ic ism and Limitat ions 
The main flaw attributed to observational studies concerns the validity of their 
conclusions. Because there is no randomization, there is a high risk of bias: its cohorts or 




unidentified confounding variables that may lead to spurious or biased connections, such as 
(but not limited to) age, socio-economical status and education (Benson & Hartz, 2000; 
Mausner & Kramer, 1984). Consequently, the hierarchy of research designs in medicine 
favors clinical trials over observational studies, mainly based on a series of comparative 
studies from the 1970s and 1980s that show that biases in observational studies render more 
positive results than corresponding trials (Benson & Hartz, 2000). 
The obvious limitations that observational studies have are related to the fact that they are 
not experimental, and therefore conclusions can only be ascertained over phenomena 
outside the control of the researcher. This implies that new techniques and therapies, unless 
experimented on by patients for reasons or means other than those consequential of the 
investigator’s initiative, are not in the realm of observational studies. 
2.2.1.3. Experimental Studies versus Observational Studies 
The debate has been reopened recently with some articles that show that observational 
studies’ conclusions are correct most of the time with no systematical inflation of results 
when compared to clinical trials on the same subject, possibly due to better data sets and 
newer statistical methods (Benson & Hartz, 2000; Concato et al., 2000). Other authors show 
high correlation between the results of the two types of studies, although with some 
variability in the magnitude of the efficacy of the treatments tested (Ioannidis & Haidich, 
2001). Arguments for the control of bias have also been argued for outside the medical 
literature (Shadish, Clark, & Steiner, 2008) 
Several authors argue that observational studies and clinical trials should not be held one 
against the other, but should rather be addressed as complementary, and the focus should 
be on understanding their strengths and weaknesses and their uses (Concato et al., 2000; 
Friedman et al., 2010). 
3. Methods 
Figure 2 outlines the methodology used in this work. The analytical method chosen to 
develop this study is grounded theory (Glaser & Strauss, 1967). This method of analysis is 




(Egan, 2002). It is particularly useful when there is not yet a developed theory that 
appropriately describes the phenomenon in study (Glaser & Strauss, 1967). In fact, although 
there is some literature on diffusion to the market and to established communities (e.g. 
Baldwin et al., 2006; Franke & Shah, 2003), peer-to-peer diffusion of innovations and its 
relation to validation practices is, to our knowledge, largely unexplored by user innovation 
theory in general, and patient innovation literature in particular. The gap in the literature that 
motivated this investigation is consequence of the literature review developed in the context 
of this master thesis. This approach was taken with great care, given that in grounded theory 
analysis, pre-conceived theoretical frameworks may bias the process of inferring theory from 
data (Glaser & Strauss, 1967). To address this issue, at each step we introduced activities to 
challenge inference from the data. 

































We begin our grounded theory process with data collection. To identify cases of patient 




searching, including online newspapers and the MIT Inventor of the Week archive with 100 
medicine and health innovators4. The most valuable resource was the literature on patient 
innovators (Shcherbatiuk & Oliveira, 2012). In online searching, we used keywords that 
include combinations and variations of “patient”, “inventor”, “innovator”, “entrepreneur”, “built 
his/her own”, “medical device”, “necessity is the mother of invention” and “cured him/herself”. 
Of the many innovators identified from both sources, we only considered patient 
innovators that created innovations primarily for their own use, or of someone close to them, 
as defined in the user innovation theory (Shcherbatiuk & Oliveira, 2012; von Hippel, 2005). 
Our sample was further reduced by our choice to only consider primary sources of 
information, the patient innovators. As a consequence, the sample consists only of 
individuals still living – which unfortunately is often not the case. In addition, we could not find 
contact information for all the innovators. 
The final sample consists of a total of 57 patients, caregivers or family members who were 
innovators, of which 22 (39%) were found in Shcherbatiuk and Oliveira’s database (2012). 
Croswell (1998) proposes that the following steps in grounded theory building are open 
coding, in which data is categorised; axial coding, in which the central phenomenon is 
identified, as well as its relations to other categories; and finally the proposal of a theory. 
The process of open coding was initiated when we started collecting data. We conducted 
three semi-structured phone calls with patient innovators who were readily available, to learn 
about their experiences in innovating and diffusing, from inception to present state. 
To perform open coding, we sought to divide the data collected in sets of categories that 
put together multiple observations. Table 1 outlines some of the category sets identified. For 
example, one of the interviewed patients shared their innovations with doctors with the main 
purpose of asking for medical feedback, whereas another did so with the main intention of 
getting them to test the solutions on other patients.  From this information we generated the 
category “motivation” that is further divided in subcategories, two of which represent the 
described cases. 
 





Table 1 - Outcome of coding – central phenomena and related categories 
Central 
phenomena 





Means of reaching Actors 
Feedback 
Active request 




Within the process of axial categorisation we find that central to the phenomena observed 
are “diffusion” and “feedback”. The grouping of categories generated in open coding and 
central phenomena is represented in table 1. Diffusion appears to form an iterative process 
of feedback that has some impact on the innovation itself, and that not only different actors 
have different feedback outputs, but also that different types of diffusion may lead to different 
types of feedback. Instances of verbal feedback ought to have a significantly different impact 
on the medical innovation than feedback from other patients who experimented the 
innovation on themselves, for example. This process is graphically represented in Figure 3. 












Between axial coding and building of the theory, more data was required with a higher 
degree of structure. Taking advantage of the contact list of patient innovators previously 
created, an online survey was developed. 
3.1. Online Survey 
As the categories and phenomena related to our research questions were emerging we 
developed a survey to further explore our findings in a more structured way, using our 
sample of 57 patient innovators identified. The survey embodied open and closed questions 
(see Appendix 2). It was sent to the 57 patient innovators identified and answered by 12, only 
10 of which completed all the answers. 
The draft version of this survey was pre-tested on a group of academic colleagues and 
improved based on their feedback. All questions in the survey were referring to the periods 
before health regulators were involved. This information was communicated to the survey 
respondents in a clear, simple, and visible manner. Involving health regulators in this 
research is interpreted as a point from where innovations enter standardized process of 
validating medical innovations. Our focus of analysis was the exploration of the informal 
ways with which patient innovators attempted to validate and diffuse their innovations. 
The survey is divided in three parts. The first part aims to capture information on the 
innovations developed (description) and its effect on the innovators’ lives, as well as to 
establish the motivations for its development. This latter point serves the purpose of 
understanding if respondents are user innovators in concurrence with the theory, namely if 
they expected high personal benefits from creating their innovation (von Hippel, 2005). 
Where possible we apply measures already used in the extant academic research. The 
levels of satisfaction with the standard of care and with the patient innovation is measured on 
7-point Likert scales (as in Oliveira et al.) We adapted scales used by Lüthje et al. (2002) to 
measure the newness of the solution, the personal benefit of creating it and the market 
demand perception. 
The second part of the survey aims to explore further roles of different subcategories of 
people identified as relevant in the open categorisation phase. We divided the population of 
targets of diffusion between family members and friends, doctors, others (e.g. academics or 




people. Related to each of these groups, the patient innovators were asked whether they 
discussed, shared or showed their innovation with each. They were asked to code their 
motivations for diffusion (including receiving feedback or advice, testing, altruism (“help other 
patients”), profit, funding, business partnership and recognition). Then, they were inquired 
whether they asked and/or received feedback. As a proxy for understanding if validation 
occurred as a consequence of diffusion, they were asked whether the feedback received had 
led to modifications of the innovation. 
The third part of this survey is developed with the main purpose of understanding if and 
how structured were any attempts to validate informally their innovations, in the form of 
studies or trials. Additionally, we tried to identify the sources of resistance that patients-
innovators were faced with throughout the whole process. 
Where appropriate we offered open-ended questions to allow for maximum collection of 
information. 
4. Results 
4.1 Survey Results 
Patient innovators reported, on average, a significant difference of quality of life before 
and after having developed their innovation (from 2 before to 6 after, in a scale of 1 to 7). 
This result is significant but may, nonetheless, be distorted by self-reporting bias by under- 
and over-evaluation of, respectively, perceptions pertaining to the moments before and after 
the innovation. Patients identified as the main reasons for creating their solutions personal 
use (or of a family member), learning or developing new skills and helping others. They have 
identified likely commercial adoption of and personal benefit from their innovation (at the time 
of development) at approximately 5 in a scale of 1 to 5. 83% of respondents experimented 
their innovations on themselves, and all of them reported that self-testing directly led to 
modifications on their innovations. 
Table 2 shows how and with whom the patient innovators shared information about their 
innovation, and the outcomes of these activities. The results suggest that patient innovators 




doctors were identified as the ones providing less feedback or advice (60%). One patient 
illustrates this in an open answer of the survey: “they [my doctors] seemed not to have much 
time to spend on me or the idea.” 
Patient Innovators in our sample have all indicated that at least one patient and at least 
one “other (e.g. academic or engineer)” had impacted the innovation. This impact on the 
innovation is in fact a source of validation, be it general praise or criticism or more 
constructive interactions, such as suggesting changes to the original innovation or its use. 
The results suggest that validation is iterative and occurs as a consequence of the patient 
innovators having diffused their innovations.  
 
Table 2 – Diffusion and Feedback 
 
When the means patient innovators used to reach other people are considered, the 
results suggest that personal connections play a significant role. Most of the groups with 
which patient innovators communicate are either already known (naturally, family members 
and friends, and doctors) or contacted by referral from others. Internet (both searches and 
website/blogs) plays an important role in connecting patients but also finding individuals with 
specific type of knowledge (technicians and academics). These results are shown in Table 3. 
 
 










Family members and friends 100% 91% 91% 70% 
Doctors 92% 60% 90% 67% 
Patients 92% 89% 78% 100% 
Manufacturers and business 
people 
75% 100% 100% 71% 
Others (e.g. engineers, academics) 67% 100% 100% 100% 
Lawyers 58% 100% 100% 29% 
















Doctors 83% 17% 0% 0% 8% 
Family members and friends 100% 25% 0% 0% 8% 
Patients 33% 42% 33% 0% 25% 
Manufacturers and business people 25% 50% 8% 8% 8% 
Caregivers and nurses 25% 25% 17% 8% 8% 
Lawyers 17% 25% 17% 8% 0% 
Patent office 17% 42% 8% 0% 0% 
Others (e.g. engineers, academics) 33% 17% 25% 0% 17% 
 
The main motivations for diffusion to other groups of people were the pursuit of validation, 
both from feedback and testing, the latter especially relevant regarding patients (to test on 
them) and doctors, nurses and caregivers (to test on other patients). Generosity or altruism 
also plays a great role, with recognition being credited by patient innovators as the less 
important factor to motivate their sharing. These results may be distinctive to this specific 
group of user-innovators. In contrast, in open source communities, for example, enjoyment-
based intrinsic motivations are identified the strongest drivers for innovation and diffusion 
















Table 4 – Motivations for dif fusion (al l  measures are on the fol lowing scale: 1 – Not 
important; 2 – Somewhat important; 3 – Very important) 
 
The results suggest that despite most of the patient innovators having thought of doing 
some trial or study (85%), only 38% undertook some sort of testing scheme, of which only 
20% appear to be structured (Figure 4). Some examples: “Asking questions, encouraging 
them to have sleep tests using the device”, “Opinion of patients” and “gave to many patients 
to experiment over the years”. Patient innovators interviewed pinpointed money, regulations 
and time as the main deterrents for the development of a trial or study. Other resistance 














To ask for feedback / advice 2,6 2,6 2,6 2,9 2,6 3,0 2,8 
To help other patients 2,9 2,0 2,8 2,7 3,0 1,5 2,2 
To sell to them 1,7 1,4 2,0 2,4 2,0 1,7 1,2 
To get funding 1,8 1,6 1,6 2,3 1,5 1,3 1,6 
Recognition 2,0 1,2 1,5 1,9 1,8 1,0 1,6 
Business partnership 1,8 1,5 1,1 2,6 1,5 1,3 2,2 
To test the solution on them 1,7 1,5 2,6 1,7 2,3 1,5 1,8 
To test the solution on other 
people 

























4.2. Process Model Proposal 
We structure the observed processes of patient innovation diffusion and propose a 
process model for an iterative process in which incremental validation of the innovation is 
performed after, and because of, diffusion to other people (Figure 5). This process model is 
characterized by feedback loops that lead to new iterations of the innovations, enabling its 
continued improvement. 
 
Three types of feedback loops were observed. The first is the consequence of self-testing: 
the patient innovator, or the person at their care, usually experiments the solution on him or 
herself. Of our 83% of survey respondents who have self-tested, 100% have indicated this to 
be a direct cause of modifications over the original innovation. The second type of feedback 
loop is what we call verbal or technical feedback, which includes medical, technical, legal or 
emotional counsel or advice. Relevant actors providing this type of feedback include doctors, 
family and friends, technicians, researchers, nurses and caregivers. The third type of 
feedback loop is also the consequence of experimentation, but of other patients. It includes 
data and verbal accounts, both structured and unstructured, of outputs, means of 













































process. Although patients can also be involved in verbal or technical feedback, they are, 
other than the inventor, the primary source for the third type of feedback, testing the 
innovation. 
One important aspect of this model is that, other than self-testing, it is diffusion to others 
that causes the acquiring of information necessary to the creation on newer iterations of the 
innovation. 
Although the diagram presented is not exhaustive, it attempts to show the main likely 
options the patient innovators are faced with. At any point in the process, the patient 
innovators may choose to abandon the innovation altogether, as a consequence of either 
their self-testing results, the verbal or technical feedback or the testing feedback they have 
received. They may also choose to stop diffusing it for different reasons, perhaps associated 
with other resistance sources. Other options at any moment are market diffusion, either by 
setting up a firm (user entrepreneurship) or selling or licensing their innovation through an 
existing firm, and also continuing the process of peer-to-peer diffusion, through free revealing 
in their community.  
5. Conclusions and Discussion 
Patient innovators have been found to share mainly with their personal contacts - with 
family members and friends, doctors and other patients, with doctors being the group of 
individuals providing the less amount of feedback. We speculate that this may be related to 
resistance to patient-originated innovation. This is corroborated by another result of our 
survey that identifies unwillingness to take risks from doctors as a significant resistance 
source faced by patient innovators (Appendix 1). Patient innovators mainly diffuse to 
communities of people they already know or ask their communities for referrals to reach 
other people with the purpose of diffusing to them. This is in line with previous literature, 
which refers to user-innovators sharing with their communities (Baldwin et al., 2006; Franke 
& Shah, 2003). However, the Internet seems to play an important role especially in the 
recruitment of other patients, and establishing links with individuals with complementary 
knowledge to what the innovators want to achieve (academics and engineers). This may be 




tools for recruitment of patients and venues for establishment of networks for the sharing of 
experiences between patients of the same diseases and individuals with skills and 
knowledge that may help patients embody their ideas for innovation. 
Diffusion was shown to have impact in the innovations themselves, via the two described 
feedback loops. The entire sample identified other patients and other people (technicians, 
engineers, academics) as groups of people whose feedback impacted led to modifications in 
the innovations. One patient who developed an insulin pump hints the reasons why, when 
asked why they had not shared with doctors: “Because my solution is oriented to patients’ 
everyday use and, as a diabetic patient, I think that the patients are the ones that have the 
knowledge in the topic of everyday use of the device. I consulted the technical aspects with 
engineers, because I know my doctor doesn't really know about insulin maintenance.”  
Based on these results, we propose that the act of diffusion not only precedes but causes 
a process of incremental validation, through feedback loops that cumulatively lead to 
modifications in the innovations, consistently with the process model detailed above. This 
premise is strengthened by the fact that the main motivations we found for the diffusion 
actions were to obtain feedback or advice and for patient testing purposes. 
However, the validation phenomena observed are rather unstructured. Incremental 
validation, as defined in this work and based on the interviews, can be attained by two 
different methods: one is by getting feedback or advice from different people, the other from 
having other people test the innovation on themselves (see Figure 4). The latter, however, 
can itself be done in many different ways, with different degrees of structure, accuracy and, 
consequentially, scientific credibility. We define a structured study as one bearing at least 
two of the fundamental marks of clinical trials, outlined before: controlled, randomised, and 
blind testing. Similarly, observational studies should only deemed structured in case of 
statistic treatment of results to remove or reduce bias. 
What we have found is that despite most of the respondents having declared interest in 
developing some form of trial or study, only approximately 38% actually self-reported having 
developed some sort of testing, and of these we considered only 20% as structured 
attempts. Some patient innovators developed surveys to scan the market before developing 




statistical techniques to avert bias and very few used any form of controls. None of the trials 
in our sample involved blinding. 
5.1 Contrasting the model with current practices in medicine 
We contrast the model proposed with a general streamlined process of randomized 
clinical trials, outlining some differences and similarities. The objectives of contrasting them 
are 1) to consider if the structure and execution of clinical trials and observational studies 
may be of help to improve these patient-led informal studies and 2) to consider whether the 
practices of informal validation by patient innovators can help in addressing some of the 
limitations and criticisms of clinical trials.  
  
One point of divergence between the two models concerns the sequence of diffusion and 
validation. Whereas in typical clinical trials for drugs and medical devices innovations have to 
be proven safe and, in some cases, proven effective before they can be marketed and used 
by patients outside the control of practitioners, in the case of patient innovators what we see 

























before there is reliable data on safety and efficacy other than that obtained through self-
validation. 
Some of the main characteristics of clinical trials and observational studies were not found 
in the majority of patient innovators cases analysed. When compared to the building blocks 
of clinical trials, the testing procedures in which patient innovators engage are limited in 
number and in structure and lack controls, blinding, and randomization. When compared to 
observational studies, the main difference is that patient innovators are not using statistical 
techniques to avert or reduce selection bias. 
Comparing clinical trials with observed practices of informal validation is particularly 
interesting from the perspective of the limitations and objections to clinical trials, namely high 
costs, long duration, low patient recruitment, design rigidity, and ethical issues. 
Although we did not directly collect data related to the costs associated with the validation 
attempts, the fact that people diffused and requested feedback mainly to and from people 
already known or that someone referred them to shows that at least the costs of recruitment 
of potential testers and collection of technical, medical or legal advice are low. 
Long duration is generally not a pressing issue for patients in informal validation 
processes. The reason for this is that other patients are experimenting, thus having access to 
the innovation during the process of validation. Given that adaptations can occur at any point 
during iterative validation, the hypotheses, testing procedures and innovations under testing 
are flexible. This means that, for example, if an innovation is slightly improved or modified, 
the patient innovator can simply ask their fellow patients to experiment with it without having 
to redesign testing procedures or having to find a new population of testers. In contrast, the 
hypotheses and procedures in clinical trials are generally rigid and stay fixed in a trial 
process. If any change is needed the trial process is restarted. 
The main ethical issues of clinical testing in patients are mainly related to the impossibility 
of research organisations to knowingly expose patients to situations where they know the 
risks outweigh the expected benefits. In these informal settings, however, patients 
themselves self-select to experiment with solutions, given their high need and dissatisfaction 
with the standard of care. Patient recruitment is thus lower than in clinical trials, also due to 




because of the incremental manner in which validation is performed, the decision of initiating 
or not the study should be less dependent on the amount of testers available. 
In what concerns patient recruitment, we cannot speculate to the differences of ease of 
recruitment of the two processes. Whereas in clinical trials there may be ethical, 
bureaucratic, and geographical barriers to patient accrual, in informal studies initiated by 
patient innovators credibility and safety barriers may hinder ability to recruit patient. However, 
unlike most clinical trials, because of the incremental manner in which validation is 
performed, the decision of initiating or not the study should be less dependent on the amount 
of testers available at the onset of the study. 
Because there is no randomisation used in most of the validation practices observed, and 
due to the self-selection of most patient that experiment with the innovations in this sample, 
these observed processes of patient innovators have higher resemblance to observational 
studies than to clinical trials. However, the lack of structure or, more exactly, the absence of 
attempts to control for selection bias with any statistic techniques, leads us to classifying 
most of these processes as informal observational trials. These informal observational trials 
have generally no formal study design, which if existent could render the validation attempts 
more sound and valid, better convincing the scientific community of its merits, and perhaps 
informing future clinical trials. 
5.2. Policy and Managerial Implications 
The phenomenon of informal validation of patient innovators is happening, and it is seems 
it is here to stay. The key questions are what can we as a society do to make it better, and 
what can we learn from it?  
Our results and model show that the observed processes of diffusion initiated by patient 
innovators play a major role in the informal validation of their innovations. The two feedback 
types observed, verbal feedback from the communities where the patients are embedded in, 
and data collected by other patients experimenting with the innovation, suggest possible 
areas around which to focus when considering ways to improve this process and increase 
individual and societal benefit. The help may consist of providing venues for information 
exchange to happen, increasing the reach to patients and other people to increase verbal 




Our data, research (e.g. Kuene et al. 2012), and common knowledge suggest internet 
and, in particular, online communities and blogs as potential venues for information 
exchange, collaboration in innovation development, and accumulation of valuable knowledge 
about experiences related to diseases and solutions to fight them. Yet the problem is to 
gather a critical mass of patients that would extend the reach of patients interested to share 
their innovation and possibly get feedback. We review below some of the attempts to provide 
such a venue – online platforms for patients and medical professionals. 
When the quality of the feedback is considered, it is instrumental to ensure that there is 
some structure in the process and that the information gathered can be used for informing 
other clinical trials or the scientific community. This structure can exist in the form of reducing 
bias through the use of statistical tools or by performing random, blind controls whenever 
possible. In lay terms, it is important to increase scientific language and methods as the 
preferred choice for communication among patients who innovate, provide feedback, and 
experiment.  
A good way to ensure the quality of the feedback is by providing of tools and practical 
guidance for patient innovators. This needs to be carefully balanced so that the process is 
not introducing too much of a burden to innovators and decreases the chances of the tools 
being used. 
The lack of tools for control and advising for patient innovators looking to test and improve 
their creations and for patients in desperate situations, hoping to experiment with the latest 
ideas and innovations, may pose higher threats to public health than if the process is guided 
and assisted. However, providing guidance and assistance opens a number of issues, from 
legal responsibility in case of mistreatment to a threat of bureaucratizing the process to an 
extent that inhibits further development of innovations.  
While to this point we referred mainly to the policy makers role, most of the considerations 
also represent opportunities from a managerial perspective. This relates to development of 
venues and tools, but also education and guidance services, for both entrepreneurs and 
healthcare-related companies. 
A number of online venues for research entities, medical professionals, and patients have 




no intention of being a thorough enumeration of current validating technologies, it may serve 
as indication of the rising movement of the importance of information technologies, 
specifically the Internet, in the processes of validation of medical innovations. 
The FDA is perhaps one of the first to have acknowledged the power of the web in 
crowdsourcing patients and clinicians data, having created a platform for the reporting of 
adverse effects of medical devices, MedWatch (FDA, 2013b). Also with the intention of 
reducing barriers to participation in medical validation, Pfizer has announced a virtual clinical 
trial, in which all data collected is self-reported by patients (Roehr, 2011). 
It is not only policy makers and pharmaceutical companies who are using the crowd. 
Users are starting projects that use big data and other tools that take advantage of 
information provided by other patients to further advance medical knowledge. One of these 
tools is Patientslikeme5, a for-profit “health data-sharing platform” that aggregates high 
amounts of health data to perform observational studies. A study performed in this platform 
disproved a previous scientific paper regarding the effects of lithium carbonate in 
amyotrophic lateral sclerosis (ALS), by systematically collecting and analysing self-
experimentation information provided by patients (Wicks, Vaughan, Massagli, & Heywood, 
2011). However, it does not appear to be generally suited for the testing of user innovations. 
Genomera6, another online project, is “crowd-sourcing health discovery by helping anyone 
create group health studies” (Genomera, 2013). Users are able to create their own 
communities which can help them come up with a suitable testing design for their hypothesis 
or question and others will serve as the testers, applying this design and sharing symptoms 
and outcomes. Randomise Me7 is a website dedicated at providing any person tools to 
create their own randomised, controlled trial, either individual or collective, with a tutorial to 
explain the building blocks of trials. Some examples of trials made include “Does eating 
cheese give you nightmares?” and “Does listening to the song that has been stuck in your 
head help you forget about it”, which, albeit humorously, show how similar questions could 







be posed for testing therapies and solutions patient innovators have came up with, helping 
validate both their self-testing and the results of the testing of others. Another interesting 
company, named Quantified Self8, “is an international collaboration of users and makers of 
self-tracking tools”, organising a community of people with the purpose of helping others “get 
meaning out of their personal data” (Quantified Self, 2012). These and many other online 
“health 2.0” platforms have a common role of innovation intermediaries (Kuenne, Temidayo, 
& Moeslein, 2013).   
Some issues should be raised with some of these tools, however. Self-reporting bias is a 
problem that should be accounted for, possibly with the use of controls. Variability in the 
testing patients’ ability to apply and test the innovations may also pose problems, and this is 
especially important with medical devices, given that drugs generally require less technical 
skills and have thus greater uniformity in its use (Christensen et al., 2007). 
This work also provides keywords and criteria to help others find cases of patient 
innovators for further studies of the phenomenon. 
5.2.1. Implications for the Patient Innovation project 
This study has important managerial and policy implications for the current practices of 
validation and diffusion of heath-care innovations, and more specifically for those developed 
by patients of chronic diseases, as pointed out in 5.2.. 
Furthermore, this study is integrated in a larger and international research project entitled 
"Patient Innovation", which is responsible for the creation of a non-profit international, 
multilingual and free platform9, designed to allow patients and caregivers to show and share 
their answers and practical solutions developed to fight their diseases. By sharing, patients 
may help themselves and others, stimulating value creation from the network effect – the 
contributions of others for the same solutions or alternatives helps create a unique database 
of solutions developed by patients with different diseases. This database is searchable by 
diseases, solutions and symptoms, and is self-managed by patients. 
                                                
8 http://quantifiedself.com 




The learning acquired in this paper may allow for a better understanding of what patient 
innovators are doing, mainly in what concerns their diffusion and validation practices, as well 
as identification of resistance sources. We feel that the perceived need for validation tools for 
patient innovators should prove important to the development and eventual success of the 
Patient Innovation platform. To be more specific, the main take ways presented here, and its 
implications, will be further developed to be presented to the Advisory Board of the Patient 
Innovation, which include five renowned scholars and scientists, including two Nobel 
Laureates10. 
5.3. Limitations 
The sample used in this analysis is mainly comprised of cases that can be considered 
successful, in which there were some diffusion attempts that led to us finding them online. 
Therefore, the results give no perspective on the incidence of diffusion among patient 
innovators in general, which may provide interesting results on understanding the most 
successful diffusion and validation practices. 
There are other sample issues that may be overcome with a different study. First, all the 
results were found online, thus excluding other offline sources, such as hospitals and 
doctors’ offices. Secondly, although we attempted to communicate with 57 patients, the 
survey includes only responses from 12 patient innovators, of which only 10 were complete. 
There are, undoubtedly, many other patient innovators out there. Finally, our sample was 
mainly of Canadians and Americans; other populations might have generated different 
results. 
Patient innovators may also incur in some misrepresentation in the answers they provide. 
In one of our interviews, one patient informed us that he had shared with no other patients, 
                                                
10 The members of the Advisory Board of the PAtient Innovation project include: 
• Prof. Aaron Ciechanover, Professor, Technion-Israel Institute of Technology 
(Nobel Laureate in Chemistry 2004) 
• Prof. Eric von Hippel, Professor, MIT Sloan School of Management  
• Prof. Katherine Strandburg, Professor, New York University School of Law 
• Sir Richard Roberts, Chief Scientist, New England Biolabs (Nobel Laureate in 
Physiology or Medicine 1993) 




only to recant himself in a later email explaining that he was afraid that by sharing with 
others, which he did profusely, he was in some way breaking the law. This is an indication 
that patient innovators may have understated the number of attempts they made of having 
other patients experiment their innovations. 
5.4. Future Research 
The grounded theory method allows for discovering hypothesis as the data is analysed, 
expectedly with fewer preconceptions than in most other empirical scientific methods. We 
have outlined some trends in the processes of diffusion and validation of patient innovators, 
in a sample of mostly successful cases, of which diffusion was effective. 
Further research is required to understand what happens in different, larger samples of 
patient innovators. Furthermore, this study of patient-to-person diffusion should be studied in 
a broader population of patients that does not only include successful patient innovators, to 
understand on the one hand which diffusion behaviours and, on the other, if validation 
initiatives led to higher success rates of the innovations. 
Peer-to-peer diffusion practices observed in this project may not be exclusive to the 
medical field, and further studies on the diffusion of innovations, both products and services. 
A larger understanding of the pitfalls and successes of the behaviours and agents innovators 
contact in their attempts to diffuse and get market and technical feedback may help future 
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Appendix 1 – Resistance measures 
 None Low Medium High 
Lack of technical skills / knowledge 20% 0% 60% 20% 
High standards for scientific proof and regulatory approval (e.g. clinical 
trials) 
40% 10% 0% 50% 
Strong intellectual property (e.g. patents) and other legal constraints 20% 20% 30% 30% 
Ethical concerns 56% 33% 11% 0% 
Unwillingness from doctors/researchers to take risks 10% 40% 20% 30% 
Lack of financial resources 10% 10% 0% 80% 
The invention has only little commercial value/market potential 20% 50% 20% 10% 
Lack of time 20% 10% 40% 30% 
Other 50% 0% 0% 50% 
 
Appendix 2 – Survey Script 
All the questions in this survey are related to your solution and the steps undertaken by 
you in showing it to other people. We are interested in your actions before engaging any 
health authority (e.g. FDA, Health Canada, EMEA, Institutional Review Board, Ethics 
Committee). Our interest is to understand whether and how patient innovators get feedback 
from others in the initial stages of development of their solution. 
 
1. Please describe the problem that motivated your solution. e.g. the condition from which 
you (or a family member) suffered. 
 
2. Please identify your level of satisfaction with the solutions available for your problem (or 
your family member's) before your innovative idea. 
(1 - Very Dissatisfied; 7 - Very Satisfied) 
 
3. Please describe your innovative idea as specifically as possible so that we can 
understand it fully. 
 
4. Please identify your level of satisfaction with the solution you created. 





5. For each line, please choose to which of the statements you identified your solution 
more with when you decided to develop it. 
• 1 - It is a small improvement / modification of an existing solution; 5 - It is a totally 
new solution 
• 1 - I would (or my family member) personally benefit very little from the solution; 5 - I 
would (or my family member) personally benefit very much from the solution 
• 1 - Few people would adopt this solution if commercially produced; 5 - Many people 
would adopt this solution if commercially produced 
 
6. How important were the following reasons for the creation of your innovation? 
(1 – Not important; 2 – Somewhat important; 3 – Very important) 
• For personal use/for the use of a family member 
• For pleasure/entertainment 
• To learn/develop new skills 
• To sell/make money 
•  To help others 
• Other (Which?) 
 
7. In which year did you start developing and/or applying your solution? 
 
8. Did you try your solution on yourself (or your family member)? 
(Yes; No) 
 
9. Did you change/tweak it as a direct consequence of having tried it on yourself (or your 
family member)? 
(Yes; No) 
10. Approximately how many times did you modify your solution? 
 
11. With approximately how many people did you share your solution? Before engaging 
with health regulators (e.g. FDA, Health Canada, EMEA) 
 
12. With whom did you discuss, share or show your innovation? Before engaging with 
health regulators (e.g. FDA, Health Canada, EMEA) 
• Doctors  
• Family members and friends  
• Other patients  
• Manufacturers and business people 





•  Patent offices  
• Others (e.g. engineers, academics) 
 
13. How did you find/reach them? 
(For each of the selected groups of people) 
• I already knew them 
• By referral from others 
• Internet search 
• Media (e.g. TV, newspapers) 
• Blog or website 
• Social network 
• Other (Which?) 
 
The following questions are related to doctors.  
 
14.1 Why didn't you show, share or discuss your solution with them? 
(Shown only if doctors were not selected) 
 
14.2 With how many did you discuss, share or show your solution? 
 
14.3 How important were the following reasons for showing, discussing or sharing your 
device with them? 
(1 – Not important; 2 – Somewhat important; 3 – Very important) 
• To ask for feedback / advice 
• To help other patients  
• To sell to them  
• To get funding 
• Recognition  
• Business partnership  
• To test the solution on them 
•  To test the solution on other people 
• Other (Which?) 
 
14.4 Did they give you feedback, advice or suggestions? 
(Yes; No) 
 






14.6 Did this feedback lead to modifications in your solution? 
(Yes; No) 
 
14.6.1 Why not? 
 
The following questions are related to family members and friends.  
 
15.1 Why didn't you show, share or discuss your solution with them? 
(Shown only if doctors were not selected) 
 
15.2 With how many did you discuss, share or show your solution? 
 
15.3 How important were the following reasons for showing, discussing or sharing your 
device with them? 
(1 – Not important; 2 – Somewhat important; 3 – Very important) 
• To ask for feedback / advice 
• To help other patients  
• To sell to them  
• To get funding 
• Recognition  
• Business partnership  
• To test the solution on them 
•  To test the solution on other people 
• Other (Which?) 
 
15.4 Did they give you feedback, advice or suggestions? 
(Yes; No) 
 
15.5 Did you ask for feedback, advice or suggestions? 
(Yes; No) 
 
15.6 Did this feedback lead to modifications in your solution? 
(Yes; No) 
 
15.6.1 Why not? 
 





16.1 Why didn't you show, share or discuss your solution with them? 
(Shown only if doctors were not selected) 
 
16.2 With how many did you discuss, share or show your solution? 
 
16.3 How important were the following reasons for showing, discussing or sharing your 
device with them? 
(1 – Not important; 2 – Somewhat important; 3 – Very important) 
• To ask for feedback / advice 
• To help other patients  
• To sell to them  
• To get funding 
• Recognition  
• Business partnership  
• To test the solution on them 
•  To test the solution on other people 
• Other (Which?) 
 
16.4 Did you try to measure in any way the effects of the use of your solution? 
(Yes (How?); No) 
 
16.5 Did they give you feedback, advice or suggestions? 
(Yes; No) 
 
16.6 Did you ask for feedback, advice or suggestions? 
(Yes; No) 
 
16.7 Did this feedback lead to modifications in your solution? 
(Yes; No) 
 
16.7.1 Why not? 
 
The following questions are related to manufacturers and business people. 
 
17.1 Why didn't you show, share or discuss your solution with them? 
(Shown only if doctors were not selected) 
 





17.3 How important were the following reasons for showing, discussing or sharing your 
device with them? 
(1 – Not important; 2 – Somewhat important; 3 – Very important) 
• To ask for feedback / advice 
• To help other patients  
• To sell to them  
• To get funding 
• Recognition  
• Business partnership  
• To test the solution on them 
•  To test the solution on other people 
• Other (Which?) 
 
17.4 Did they give you feedback, advice or suggestions? 
(Yes; No) 
 
17.5 Did you ask for feedback, advice or suggestions? 
(Yes; No) 
 
17.6 Did this feedback lead to modifications in your solution? 
(Yes; No) 
 
17.6.1 Why not? 
 
The following questions are related to caregivers and nurses.  
 
18.1 Why didn't you show, share or discuss your solution with them? 
(Shown only if doctors were not selected) 
 
18.2 With how many did you discuss, share or show your solution? 
 
18.3 How important were the following reasons for showing, discussing or sharing your 
device with them? 
(1 – Not important; 2 – Somewhat important; 3 – Very important) 
• To ask for feedback / advice 
• To help other patients  
• To sell to them  





• Business partnership  
• To test the solution on them 
•  To test the solution on other people 
• Other (Which?) 
 
18.4 Did they give you feedback, advice or suggestions? 
(Yes; No) 
 
18.5 Did you ask for feedback, advice or suggestions? 
(Yes; No) 
 
18.6 Did this feedback lead to modifications in your solution? 
(Yes; No) 
 
18.7 Why not? 
 
The following questions are related to lawyers.  
 
19.1 Why didn't you show, share or discuss your solution with them? 
(Shown only if doctors were not selected) 
 
19.2 With how many did you discuss, share or show your solution? 
 
19.3 How important were the following reasons for showing, discussing or sharing your 
device with them? 
(1 – Not important; 2 – Somewhat important; 3 – Very important) 
• To ask for feedback / advice 
• To help other patients  
• To sell to them  
• To get funding 
• Recognition  
• Business partnership  
• To test the solution on them 
•  To test the solution on other people 
• Other (Which?) 
 






19.5 Did you ask for feedback, advice or suggestions? 
(Yes; No) 
 
19.6 Did this feedback lead to modifications in your solution? 
(Yes; No) 
 
19.6.1 Why not? 
 
The following questions are related to other people (e.g. engineers, 
academics). 
 
20.1 Why didn't you show, share or discuss your solution with them? 
(Shown only if doctors were not selected) 
 
20.2 With how many did you discuss, share or show your solution? 
 
20.3 Please name their professions. 
 
20.4 How important were the following reasons for showing, discussing or sharing your 
device with them? 
(1 – Not important; 2 – Somewhat important; 3 – Very important) 
• To ask for feedback / advice 
• To help other patients  
• To sell to them  
• To get funding 
• Recognition  
• Business partnership  
• To test the solution on them 
•  To test the solution on other people 
• Other (Which?) 
 
20.5 Did they give you feedback, advice or suggestions? 
(Yes; No) 
 
20.6 Did you ask for feedback, advice or suggestions? 
 






20.7.1 Why not? 
 
21. Please provide a general sequence of the people to whom you showed your solution 
by dragging the alternatives. 1 is first, 2 is second, etc. 
• Doctors 
• Other patients 
• Caregivers and nurses 
• Patent office 
• Family members 
• Manufacturers 
• Lawyers 
• Others (e.g. engineers, academics) 
 
22. Did you get unrequested feedback from people reached through any of these means? 
(Yes; No) 
• Media (e.g. TV, newspapers) 
• Blog or Website  
• Social network  
• Other 
 
22.1 Did this feedback lead to modifications in your solution? 
(Yes; No) 
 
23. Before engaging health regulators, did you think of doing some sort of study or trial? 
(Yes; No) 
 
24. Did you actually do any study or trial? (before engaging health regulators) 
(Yes; No) 
 
24.1 Please describe it.  If it included randomization and blinding, please include it in your 
description. 
24.2 Why not?  You may select more than one. 
• Patient recruitment 
• Financial reasons 
• Time 
• Problems with the solution 
• Regulatory/legal concerns 










•  Health Canada 
•  Ethics Committee or Institutional Review Board 
• Other(s) (Which?) 
 
26. In which year did you first engage a health regulatory board? (e.g. FDA, Health Canada, 
EMEA) 
 
27. Did you experience any of the barriers listed below? Please indicate to which degree. 
(1 – None; 2 – Low; 3 – Medium; 4 – High) 
• Lack of technical skills / knowledge 
• High standards for scientific proof and regulatory approval (e.g. clinical trials) 
• Strong intellectual property (e.g. patents) and other legal constraints 
• Ethical concerns 
• Unwillingness from doctors/researchers to take risks 
• Lack of financial resources 
• The invention has only little commercial value/market potential 
• Lack of time 
• Other (Which?) 
 
28. Did you file a patent for your solution? 
(Yes; No) 
 
29. What is your age? 
 
30. In which country do you reside? 
 










Descript ion Type Online sources 
Patient ReWalk Robotic Exoskeleton for legs MD http://rewalk.com 
Daughter N/A 
Device that helps an assistance dog in 
pulling its owner's wheelchair and a dog 




Patient Diabetes Book Daily control of blood sugar TH 
http://www.diabetes-
book.com 
Nurse IV House 
“Polyethylene site protector, shaped like a 
computer mouse, that is soft, smooth-edged, 
transparent, and attachable with a single 
piece of tape. The "IV House" is safer, 
quicker and less expensive than other 






“A device that attaches the IV needle and 



















Medical UVB home phototherapy equipment 
























Patient Heal in comfort 
“ultra soft, moisture management shirt that is 
designed for comfort, as well as holding the 











Cane Massager MD http://www.theracane.com 









Patient Passy Muir 






“An intuitive pill bottle and information system 
that includes a redesigned bottle, easy-to-
read label, removable information card, color-








Recliner with with pendulum movement to 
facilitate blood circulation  
MD http://vbpmkr.com 










Epinephrine auto-injector with the height and 




Patient Log for Life On-line diabetes log MD 
http://ethanmullis.carbonmad
e.com/about 
Father The Total Knee 
A prosthetic knee suitable and safe for a 





Mixture with hot peppers extract for curing 




Patient PerfIC Cath Urinary Catheter MD 
http://www.adaptamedical.co
m 
Mother ePer 100 




















Pillow to support the ideal position for 








Patient Hanky pancreas Fashion for diabetes MD hankypancreas.com 
Patient CTi brace 
“A Knee brace that protects the knee in much 
the same way that a ski boot protects the 









Bed that facilitates the turning and 















Electro-acoustical transducer for release of 














“The world’s first bath-substituting lotion.” “A 
water-less bathing lotion (...) differing from 
the anti-bacterial hand washes by eliminating 









Patient Quietus Liners Mask liner MD http://www.quietusliners.com 



















Medical diagnostic system able to perform 
multiple tests on a sample as small as a drop 
of blood in a fraction of the time and at a 













simple but very effective device for 
preventing you, the sleeper, remaining on 









Asthma inhaler MD 
http://www.vivosmartmedical
.com/contact 
Patient Neck Brace 
Multifunctional neck brace that unloads 






"saucer-shape disc with replaceable 












Low profile, flexible neck supporter MD http://shanesneckbrace.com/  
Nurse Bili Bonnet 
Soft and flexible eye mask for premature 








Low-level laser, multimodal technology to 




Doctor Biffy Bidet 












































“Remote monitoring system that can be used 
by caregivers to keep track of the daily 
activities of elderly people who are either still 













The coding for the types of innovation is the following: MD – Medical Device; TH – 
Therapy; CO – Cosmetic; PH – Pharmaceutical . 
